Benchmark dose analyses of multiple genetic toxicity endpoints permit robust, cross-tissue comparisons of mutamouse responses to orally delivered benzo[a]pyrene

HIGHLIGHTS

• who: Alexandra S. Long from the ON K A , Canada Department of Biology, University of, ON have published the article: Benchmark dose analyses of multiple genetic toxicity endpoints permit robust, cross-tissue comparisons of MutaMouse responses to orally delivered benzo[a]pyrene, in the Journal: (JOURNAL)
• what: The authors demonstrate an emerging use of the benchmark dose (BMD)-approach for empirically ranking cross-tissue sensitivity. The authors used the prototypical genotoxic carcinogen benz pyrene (BaP), four well-characterized genetic toxicity endpoints, and the BMD approach, to scrutinise responses at low doses, rank potencies across tissues . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.